Literature DB >> 24801906

Prognostic value of CYP2W1 expression in patients with human hepatocellular carcinoma.

Ke Zhang1, Li Jiang, Rong He, Bao-Liang Li, Zhe Jia, Rong-Hai Huang, Yi Mu.   

Abstract

CYP2W1 overexpression has been reported in a variety of human cancers. However, the role of CYP2W1 in hepatocellular carcinoma (HCC) remains unclear. This study was designed to evaluate the expression and prognostic significance of CYP2W1 in human HCC. Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was conducted to detect CYP2W1 messenger RNA (mRNA) expression in 41 pairs of fresh-frozen HCC tissues and adjacent noncancerous tissues. In addition, CYP2W1 expression was analyzed by immunohistochemistry in 133 clinicopathologically characterized HCC cases. The relationship between CYP2W1 expression and clinicopathological features was analyzed by appropriate statistics. Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between CYP2W1 expression and prognosis of HCC patients. The relative mRNA expression of CYP2W1 was significantly higher in HCC tissues than in adjacent noncancerous tissues (P < 0.001). In addition, CYP2W1 expression was significantly correlated with tumor size (P = 0.023), histological differentiation (P = 0.04), and tumor stage (P = 0.014). The Kaplan-Meier survival curves indicated that patients with high expression of CYP2W1 had shorter overall survival than those with low expression (P < 0.001). Furthermore, Cox regression analyses showed that CYP2W1 expression was an independent predictor of overall survival. Our data suggest that CYP2W1 could play an important role in HCC and might serve as a valuable prognostic marker and potential target for gene therapy in the treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24801906     DOI: 10.1007/s13277-014-2023-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  14 in total

1.  Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases.

Authors:  Jian Zhou; Zhao-You Tang; Zhi-Quan Wu; Xin-Da Zhou; Zeng-Chen Ma; Chang-Jun Tan; Ying-Hong Shi; Yao Yu; Shuang-Jian Qiu; Jia Fan
Journal:  Hepatogastroenterology       Date:  2006 Mar-Apr

2.  Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells.

Authors:  Liping Du; Mark M Neis; Patricia A Ladd; Diane L Lanza; Garold S Yost; Diane S Keeney
Journal:  Toxicol Appl Pharmacol       Date:  2005-11-22       Impact factor: 4.219

3.  Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands.

Authors:  Liping Du; Mark M Neis; Patricia A Ladd; Diane S Keeney
Journal:  J Pharmacol Exp Ther       Date:  2006-09-19       Impact factor: 4.030

4.  Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1.

Authors:  Maria Karlgren; Alvin Gomez; Katarina Stark; Jenny Svärd; Cristina Rodriguez-Antona; Ernst Oliw; Maria Luisa Bernal; Santiago Ramón y Cajal; Inger Johansson; Magnus Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  2006-01-11       Impact factor: 3.575

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yubo Yang; Hiroaki Nagano; Hideo Ota; Osakuni Morimoto; Masato Nakamura; Hiroshi Wada; Takehiro Noda; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Keizo Dono; Koji Umeshita; Shoji Nakamori; Kenichi Wakasa; Masato Sakon; Morito Monden
Journal:  Surgery       Date:  2007-02       Impact factor: 3.982

Review 7.  A decade's studies on metastasis of hepatocellular carcinoma.

Authors:  Zhao-You Tang; Sheng-Long Ye; Yin-Kun Liu; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-18       Impact factor: 4.553

Review 8.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

Review 9.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

10.  The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study.

Authors:  David Edler; Kristina Stenstedt; Katarina Ohrling; Marja Hallström; Maria Karlgren; Magnus Ingelman-Sundberg; Peter Ragnhammar
Journal:  Eur J Cancer       Date:  2008-12-30       Impact factor: 9.162

View more
  7 in total

1.  KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance.

Authors:  Yanying Wang; Jianxin Jiang; Qun Li; Hong Ma; Zengguang Xu; Yong Gao
Journal:  Int J Clin Oncol       Date:  2016-04-19       Impact factor: 3.402

2.  Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors.

Authors:  Eva Choong; Jia Guo; Anna Persson; Susanne Virding; Inger Johansson; Souren Mkrtchian; Magnus Ingelman-Sundberg
Journal:  PLoS One       Date:  2015-04-06       Impact factor: 3.240

3.  Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study.

Authors:  Barbara Altieri; Silviu Sbiera; Sabine Herterich; Silvia De Francia; Silvia Della Casa; Anna Calabrese; Alfredo Pontecorvi; Marcus Quinkler; Tina Kienitz; Massimo Mannelli; Letizia Canu; Anna Angelousi; Vasileios Chortis; Matthias Kroiss; Massimo Terzolo; Martin Fassnacht; Cristina L Ronchi
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

4.  Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome.

Authors:  Dan Li; Tao Yu; Junjie Hu; Jie Wu; Shi Feng; Qingxue Xu; Hua Zhu; Xu Zhang; Yonggang Zhang; BenHong Zhou; Lijuan Gu; Zhi Zeng
Journal:  Oxid Med Cell Longev       Date:  2021-12-31       Impact factor: 6.543

5.  Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein.

Authors:  Martin J Ronis; Kelly E Mercer; Kartik Shankar; Casey Pulliam; Kim Pedersen; Magnus Ingelman-Sundberg; Simonetta Friso; Derrick Samuelson; Luis Del Valle; Chris Taylor; David A Welsh
Journal:  Chem Biol Interact       Date:  2020-05-14       Impact factor: 5.192

6.  Expression and significance of CHIP in canine mammary gland tumors.

Authors:  Huanan Wang; Xu Yang; Yipeng Jin; Shimin Pei; Di Zhang; Wen Ma; Jian Huang; Hengbin Qiu; Xinke Zhang; Qiuyue Jiang; Weidong Sun; Hong Zhang; Degui Lin
Journal:  J Vet Med Sci       Date:  2015-07-09       Impact factor: 1.267

7.  The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.

Authors:  Ryo Ashida; Yukiyasu Okamura; Keiichi Ohshima; Yuko Kakuda; Katsuhiko Uesaka; Teiichi Sugiura; Takaaki Ito; Yusuke Yamamoto; Takashi Sugino; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Oncotarget       Date:  2018-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.